Eli Lilly reported third-quarter revenue up 39% year over year to $24.4 billion, driven mainly by GLP-1 drugs: Mounjaro rose 65% to $10.7 billion and Zepbound rose 49% to $5.4 billion. Non-GAAP earnings per share were $7.48, up 7%, held back by acquisition-related expenses, but both revenue and earnings beat analyst estimates. The company raised its full-year 2026 revenue guidance to $91 billion to $92 billion from $85 billion to $87 billion, and its shares jumped after the report. The article argues the GLP-1 market still has room to expand given low penetration, and views Lilly's pipeline, including retatrutide, as among the strongest in the field, while noting pricing pressure and competition from new medicines over the medium term.
Summary written by Upside AI from the original article. Read the source for full details.
Read the original on Yahoo Finance ↗
Keywords
Eli Lillypharmaceuticalshealthcareearnings
Open a keyword to see other news on the same topic.
Related news
- Lilly’s Weight-Loss Machine Gets Even Bigger
Mounjaro and Zepbound once again drove a strong earnings beat for Lilly, along with a guidance upgrade worth billions of dollars. However, the company's new obesity pill is trailing Novo Nordisk from the start.
- Eli Lilly, IBD Stock Of The Day, Rides Foundayo, Medicare Bridge To Buy Point
- Forget Zepbound: 3 Newer Drugs That Could Power Eli Lilly's Next Leg Higher
Eli Lilly's Foundayo, an oral GLP-1 weight-loss medicine approved in the U.S. in April, is drawing new patients, with 80% of its prescriptions earlier this year going to people who had never taken a GLP-1 medicine before. The company's Onswik, a once-weekly basal insulin for diabetes approved in September, could strengthen its diabetes portfolio, though Novo Nordisk's Awiqli was approved first in March. The investigational retatrutide showed average weight loss of up to 28.3% over 80 weeks in one Phase 3 study, and Eli Lilly plans to submit it for regulatory approval in the first quarter of 2027. The article argues these drugs could power Eli Lilly's next phase of growth beyond Zepbound.
- Novo Nordisk and Eli Lilly Just Got Some Fantastic News
A mouse study funded by the NIH found that semaglutide, made by Novo Nordisk and sold as Ozempic and Wegovy, extended the lifespan of older, healthy mice by tempering aging effects, with treated mice showing better muscle and cognitive function. The author assumes that tirzepatide, Eli Lilly's main GLP-1 drug, could show similar effects, though results in humans remain a long way off. Gallup data cited in the article show that US adult use of GLP-1 weight-loss injectables has nearly quadrupled since 2024, reaching 11% this year from 3% two years ago. J.P. Morgan expects about 25 million Americans to be on GLP-1 treatment by 2030, and Morgan Stanley forecasts the market will more than double from 2025 to 2035, to $190 billion.
- Eli Lilly's Biggest Shareholder Is Selling $347 Million of Stock. Should You Sell Too?
Lilly Foundation, the largest shareholder of Eli Lilly with about 9.6% of outstanding shares, is selling 300,000 shares, worth about $347 million at the time of the announced sale. The article says this is a required annual charitable payout and does not reflect a bearish view on the stock. Lilly is leading the GLP-1 race, with tirzepatide (Mounjaro for diabetes, Zepbound for weight loss) becoming the world's best-selling drug late last year, displacing Merck's Keytruda. Morgan Stanley forecasts the GLP-1 market will more than double to $190 billion between 2025 and 2035. After a 49% share price gain over the past year, the average analyst price target is $1,328, about 10% above the current price, and the author argues there is no reason to sell.
- Eli Lilly Stock Has Pulled Back 8%. History Says This Is What Happens Next.
Eli Lilly (LLY) shares have pulled back about 8% in recent weeks, after rising 41% over the past 12 months. The article attributes the decline mainly to investors taking profits after a 50% gain in less than four months that pushed the stock to an all-time high in August. U.S. prices for its products fell 3% year over year due to Zepbound and Mounjaro, or 9% excluding rebates and discounts, and the stock trades at 38.6 times trailing earnings versus 23.6 for the S&P 500. The author argues that overwhelming demand for these drugs will keep sales rising, and that over the past 10 years the stock fell by at least 8% more than 20 times yet still returned more than 14x. Of 23 analysts rating the stock over the last three months, 20 recommend buy or better, with a consensus target implying around 16% upside.
Related markets
Latest news
- Bond Market Signals Distress About CoreWeave. Here's How To Profit From It.
As investors debate whether an AI bubble is about to burst, a few weak firms have been hit hard. CoreWeave's stock is one of them.
- This Will be John Ternus's First Earnings Call as CEO
John Ternus, described as the 'product guy,' will host his first earnings call as Apple CEO tonight, and all eyes will be on him.
- Big Tech's AI Binge Is Sinking the Market. Can Santa Save It?
Stocks are sputtering as momentum in the tech trade fades. However, a rebound from here will be difficult.
- Bitcoin risks drop below $76K as 7% oil slide fails to spark BTC price rally
Bitcoin fell about 1.7% on Monday to below $77,000 as stocks pared early gains on hopes of a diplomatic resolution to the US-Iran war. WTI crude slid over 7% to about $96.50 per barrel after touching $95.15, its lowest since Oct. 15, while Brent dropped 9% to around $103.30. Gold rebounded 2% past $3,950 per ounce after hitting 13-month lows of $3,891. Rekt Capital warned BTC could fall below $76,000 after failing to break $78,500, while QCP Capital pointed to the $76,000–$76,600 support band and $79,500–$80,500 resistance as key levels.
- How soon gas prices could go down now that oil is tumbling
Retail gas prices fell to $4.12 a gallon on Monday, as U.S. oil prices dropped below $100 a barrel. The article examines how quickly gas prices could follow the decline in oil.
- These 2 Tech Stocks Both Fell 29% on Friday. Are They Buying Opportunities Now?
Intel and Reddit both fell nearly 29% on Friday after their earnings reports, even though neither company had a bad quarter. Intel's third-quarter revenue rose 21% to $16.5 billion and beat its own guidance, but its fourth-quarter outlook of $15 billion to $16 billion fell short of the roughly $17 billion analysts expected, weighed down by PC weakness as AI data centers absorb memory chips. Reddit's third-quarter revenue rose 53% to $895 million, but search traffic fell meaningfully and U.S. daily users slipped 2% to 50.7 million. The article says Intel's problem may be cyclical, while Reddit's concern looks more lasting, since there is no guarantee AI search will drive as much traffic as traditional search did.
Get the briefing on Telegram or Zalo
Join the Upside Telegram channel or Zalo group for the Vietnam stocks and gold briefing at 8:00 and 19:00 (Vietnam time) on trading days, plus a weekly wrap on Saturday morning.